In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi AppTec Inc.

Division of WuXi PharmaTech Inc.
www.wuxiapptec.com

Latest From WuXi AppTec Inc.

Trade War‘s Next Frontier? China Genetic Material Regs Could Set Back Biopharma Research

A new rule regulating the collecting, storing and transporting of genetic samples and materials in China sets new limits on international companies looking to conduct work with biologic and gene therapies in potentially the most promising market for these emerging technologies.

China Regulation

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

Asia Executives On The Move: New Daiichi CEO, WuXi CMO

The coming of spring has seen the announcement of multiple executive moves in the Asia Pacific region, including a new CEO at Japan's Daiichi Sankyo, while WuXi Apptec and llumina have also made new appointments. Other personnel changes also take place at Shionogi Healthcare and the top of Japan's main regulatory agency.

Appointments China

Korea Suspends First Approved Gene Therapy Pending Component Discrepancy Probe

South Korea’s first approved gene therapy has been suspended from sale in the country, while recruitment in an ongoing US Phase III program has been temporarily halted, after findings that an active cell component may differ from the data submitted at the time of approval. While both manufacturer and regulator see no safety risk, results from an official Korean probe are due in mid-April.

South Korea United States
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • AppTec Laboratory Services Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • WuXi PharmaTech Inc.
  • Senior Management
  • Edward Hu, Co-CEO
    Ellis Chu, SVP, CFO
    Shuhui Chen, PhD, CSO
    Steve Yang, PhD, EVP, CBO
    Frederick H Hausheer, MD, CMO
  • Contact Info
  • WuXi AppTec Inc.
    Phone: 21 5046 1111
    Waigaoqiao Free Trade Zone
    288 Fute Zhong
    Shanghai, MN 200131
    China
UsernamePublicRestriction

Register